.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,530,661

« Back to Dashboard

Details for Patent: 8,530,661

Title:Process for the manufacture of pharmaceutically active compounds
Abstract: The present invention further relates to a process for the manufacture of compound (I), ##STR00001## wherein X is --Br or --Cl.
Inventor(s): Hildbrand; Stefan (Gelterkinden, CH), Mair; Hans-Juergen (Loerrach, DE), Radinov; Roumen Nikolaev (West Caldwell, NJ), Ren; Yi (Shanghai, CN), Wright; James Anderson (Cedar Grove, NJ)
Assignee: Hoffmann-La Roche, Inc. (Nutley, NJ)
Filing Date:Sep 13, 2012
Application Number:13/613,024
Claims:1. A process for the manufacture of compound (I), ##STR00037## comprising the steps of: aa) reacting the compound of formula (II), ##STR00038## with the compound of formula (III), ##STR00039## in the presence of a catalyst, copper(I)iodide and a base, to produce the compound of formula (IV), ##STR00040## bb) reacting said compound of formula (IV) in the presence of aqueous alkali metal hydroxide at 50-90.degree. C. and under reduced pressure to produce the compound of formula (V), ##STR00041## and cc) reacting said compound of formula (V) in the presence of aqueous alkali metal hydroxide or a strong base to produce the compound of formula (I); wherein R.sup.1 and R.sup.2 are each independently a C1-C4 alkyl, and X is --Br or --Cl.

2. The process according to claim 1, wherein X is --Br.

3. The process according to claim 1, wherein R.sup.1 and R.sup.2 are both methyl.

4. The process according to claim 2, wherein reaction step bb) is carried out under reduced pressure below 100 mbar.

5. The process according to claim 1, wherein the catalyst in step aa) is PdCl.sub.2(PPh.sub.3).sub.2 and the alkali metal hydroxide in step bb) is lithium- or sodium hydroxide.

6. The process according to claim 1, wherein the compound of formula (IV) is dissolved in a mixture of water and N-methylpyrrolidone, and is reacted in the presence of aqueous sodium hydroxide at about 75 to about 85.degree. C. and under reduced pressure for 15 to 20 hours to give directly the compound of formula (I) without the need to apply an aqueous work-up of the compound of formula (V).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc